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ReviewThe phenotypic fate and functional role for bone
marrow-derived stem cells in liver ﬁbrosis
Tatiana Kisseleva⇑, David A. Brenner
Dept. of Medicine, University of California, San Diego, CA, USASummary Myoﬁbroblasts express type I collagen and other extracellu-Liver ﬁbrosis is an outcome of chronic liver injury of any etiology.
It is manifested by extensive deposition of extracellular matrix
(ECM) proteins that produce a ﬁbrous scar in the injured liver.
Bone marrow (BM) cells may play an important role in pathogen-
esis and resolution of liver ﬁbrosis. BM cells contribute to the
inﬂammatory response by TGF-b1 secretion and activation of
liver resident myoﬁbroblasts. Moreover, BM itself can serve as a
source of collagen expressing cells, e.g. BM-derived ﬁbrocytes
and mesenchymal progenitors, which in turn, have a potential
to in situ differentiate into ﬁbrogenic myoﬁbroblasts and facili-
tate ﬁbrosis. Finally, BM cells play an active part in resolution
of liver ﬁbrosis after cessation of ﬁbrogenic stimuli. While natural
killer (NK) cells are implicated in apoptosis of activated hepatic
stellate cells/myoﬁbroblasts, cells of myelo-monocitic lineage
secrete matrix metalloproteinases to actively degrade the ﬁbrous
scar. The focus of this review is on the current understanding of
the role of different subsets of BM cells in the onset, development
and resolution of liver ﬁbrosis.
Published by Elsevier B.V. on behalf of the European Association
for the Study of the Liver.Introduction
Liver ﬁbrosis is caused by chronic injury which triggers apop-
tosis of hepatocytes, damage of the endothelial barrier,
recruitment of inﬂammatory cells, increased secretion of
TGF-b1, and activation of myoﬁbroblasts responsible for scar
formation [10,50]. However, the contribution of bone marrow
(BM) cells to liver ﬁbrosis remains controversial [44,51]. At
the onset of ﬁbrosis, BM cells are recruited to the site of injury
to facilitate inﬂammation. It is believed that monocytes and
macrophages are the primary source of TGF-b1, the major ﬁbr-
ogenic cytokine that plays a critical role in activation of ﬁbro-
genic myoﬁbroblasts.Journal of Hepatology 20
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sis. Three sources of myoﬁbroblasts have been identiﬁed:
hepatic stellate cells (HSCs) in hepatotoxic liver injury [27], por-
tal ﬁbroblasts in cholestatic liver injury [18], and ﬁbrocytes in
any inﬂamed liver (Fig. 1). Most myoﬁbroblasts retain the mark-
ers of being originally derived from either ﬁbroblasts (such as
Thy1 and elastin), HSCs (such as vitamin A droplets, GFAP, and
desmin), or ﬁbrocytes (CD45). Theoretically, myoﬁbroblasts
may also be derived directly from a precursor cell, unrelated
to stellate cells, ﬁbroblasts, or ﬁbrocytes. Cell fate mapping stud-
ies in reporter mice have demonstrated that both hepatic
stellate cells and ﬁbroblasts are septum transversum mesenchy-
mal cells that migrate from the mesothelium and submesotheli-
um C [5].
Cessation of the injury often causes resolution of liver ﬁbrosis
with resorption of the ﬁbrous scar [40,41]. Under these circum-
stances, activated myoﬁbroblasts undergo senescence [53,77,
80], apoptosis and disappear [42,73]. It has been shown that NK
(and NKT) cells facilitate aHSCs apoptosis during regression of
ﬁbrosis [72], while newly recruited monocytes actively degrade
extracellular matrix proteins (ECM) [20] via upregulation and
secretion of matrix metalloproteinases (e.g. MMP13) [95] and
collagenases [43].
Stem cell biology has become one of the most intensely stud-
ied areas of biomedical research and there is great optimism
among scientists and the lay public that stem cells will be used
as novel therapies for many incurable chronic diseases. Many
institutions, including the State of California, have committed bil-
lions of dollars speciﬁcally to promote stem cell research with the
goal of developing new therapies within a few years. As a result
of new insights into stem cells, there is a renewed interest in the
role of the bone marrow and its stem cells in liver ﬁbrosis. The
information to date is very conﬂicted, with different studies
showing either a contributing effect or a therapeutic effect of
bone marrow-derived cells to liver ﬁbrosis.
Many studies have raised the issue of whether liver myoﬁbro-
blasts may be derived from bone marrow stem cells, either hema-
topoietic or mesenchymal stem cells. Due to their well deﬁned
cell lineage markers and methodology for hematopoietic stem
cell transfer, the contribution of hematopoietic stem cells to the
population of liver myoﬁbroblasts may be readily assessed in
experimental murine liver ﬁbrosis.
This review will address three issues: (1) the role of BM-
derived macrophage to liver ﬁbrogenesis, (2) the contribution12 vol. 56 j 965–972
Bone marrow
Review
of BM cells to myoﬁbroblasts in the ﬁbrotic liver, and (3) the role











Fig. 1. Possible origins of ﬁbrogenic myoﬁbroblasts. Hepatic myoﬁbroblasts
may originate from liver resident mesenchymal cells. These include hepatic
stellate cells, which under physiological conditions reside in the space of Disse in
a quiescent state, and in response to injury undergo activation into myoﬁbro-
blasts. Portal ﬁbroblasts may also be a source of myoﬁbroblasts in the ﬁbrotic
liver. In addition, BM-derived hematopoietic and mesenchymal cells may
contribute to the myoﬁbroblast population. While the role of mesenchymal stem
cells in liver ﬁbrosis is not well characterized due to the lack of speciﬁc markers
and difﬁculties with their isolation, hematopoietic stem cells contribute to
hepatic ﬁbrocytes in response to liver injury.Inﬂammation
Expression of collagen type I marks ﬁbrogenic/hematopoietic cells
While the ﬁbrogenic properties of ﬁbrocyteswill be discussed below,
it is important to note that expression of collagen type I by hemato-
poietic cells has a critical role in the development and maturation
of hematopoietic BM cells required to mediate injury-triggered
immune responses [22,78,89]. First, activated macrophages upregu-
late collagen type I upon maturation and migration to the site of
injury [67]. Surprisingly, the level of collagen expression in activated
macrophages is similar to activated cultured ﬁbrocytes or ﬁbrocyte-
like cells [67]. Second, upregulation of collagen type I is associated
with maturation of hematopoietic stem cells [22,78,89]. It is
unknown why collagen expression is required for the function of
hematopoietic stem cells. A recent study suggested that collagen I
regulates the self-renewal of mouse embryonic stem cells through
a2b1 integrin- and DDR1-dependent Bmi-1 [89]. However, the level
of collagen expression in activatedmacrophages andﬁbrocytes is rel-
atively low compared to activated myoﬁbroblasts [67,79], so that
these cells are notmajor sources of collagen, butmost likelymediate
cellular interaction [78] with extracellular matrix causing cytoskele-
tal rearrangement [17,31,86].
Key Points 1
Collagen type I plays a critical role in differentiation and 
maturation of hematopoietic cells. Future studies are required 
cells of hematopoietic origin
to demonstrate the significance of collagen expression on theAlternative mechanisms to clear bacterial debris
Increased intestinal permeability has a critical role in the
pathogenesis of liver ﬁbrosis [81,104]. Recent studies have demon-
strated that in addition to phagocytosis, neutrophils, macrophages,
andﬁbrocytesmayutilize analternative pathway to combatbacteria,
by releasing extracellular DNA-based traps enriched in histones and
major antimicrobial enzymes, cathelescidin and myeoloperoxidase
[12,16,97,106]. It remains unclearwhy terminally differentiated cells
with phagocytic capacity decide to intake or exterminate bacteria
[16]. This mechanism is activated in Vegenar granulomatosus [46]
and Lupus nephritis [34]. Although the signiﬁcance of such phenom-
enon for liver ﬁbrosis still has to be investigated, ﬁbrocyte-like cells
from the spleen (CD45+Collagen-a1(I)+ BM-derived cells) may form
DNAtraps followingLPS-orCCl4-induced liver injury [52]. Thus, iden-
tiﬁcation and classiﬁcation of ﬁbrocytes and ﬁbrocyte-like cells
recruited to the injured liver may provide new insights into the
pathogenesis of liver ﬁbrosis.
Recruited BM macrophages induce ﬁbrosis
BM macrophages and Kupffer cells (liver resident macrophages)
are the major source of TGF-b1 in liver ﬁbrosis [81]. T and B
lymphocytes are also recruited to the site of injury and further966 Journal of Hepatology 201facilitate secretion of ﬁbrogenic cytokines. Ablation of myolo-
monocytic CD11b+ cells in mice at the onset of liver ﬁbrosis
attenuated activation of ﬁbrogenic myoﬁbroblasts and collagen
deposition in liver and kidney ﬁbrosis [20,21,45].
Bacterial ﬂora and toll-like receptor (TLRs) signaling are criti-
cal in the activation of Kupffer cells/macrophages and TGF-b1
release [81]. For example, TLR4 mutant and knockout mice are
resistant to ﬁbrosis of different etiologies [38]. Moreover, genome
wide analysis studies have demonstrated that individuals carry-
ing a low efﬁciency polymorphism in TLR4 gene are less suscep-
tible to HCV-induced liver ﬁbrosis [56]. Toll-like receptors (TLRs)
recognize pathogen-associated molecular patterns (PAMP) such
as lipopolysaccharide (LPS), bacterial cell wall component, pep-
tideglycan, and bacteria-derived unmethylated CpG-DNA [38].
In addition, endogenous ligands (alarmins, e.g. HMGB-1, hyaluro-
nan) can bind TLR4 in the presence of CD14 and LPS-binding pro-
tein [LBP) and transduce similar signals [105]. Upon activation of
TLRs, recruited BM cells produce inﬂammatory cytokines, such as
TNF-a, IL-6, IL-1, MCP-1, and RANTES [82]. Moreover, microbial
products have a signiﬁcant impact on ﬁbrogenic progression
[104], and LPS synergistically facilitates other ﬁbrogenic factors
such as TGFb-1, oxidative stress, and mechanical injury [2].
TLR4 on BM cells is important in experimental alcoholic liver
disease [39], and TL9 on BM cells is important in experimental
non-alcoholic steatohepatitis [61].2 vol. 56 j 965–972
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Antiﬁbrotic effects of macrophages
Original experiments by Dufﬁeld et al. [20] and subsequent stud-
ies [60,102] have demonstrated that, over a period of time, two
functionally distinct types of macrophages are recruited to the
injured liver. During the injury phase, pro-ﬁbrogenic macro-
phages mediate recruitment of injury-associated macrophages
that promote myoﬁbroblast proliferation and apoptosis [32]. In
contrast, during recovery from injury, a population of macro-
phages predominates that resembles classical macrophages and
does not promote HSC survival but mediates matrix degradation.
This macrophage population is present during resolution of
injury and at a time when pro-ﬁbrogenic and inﬂammatory
mediator levels are decreasing [20]. These two functional pheno-
types are separated chronologically in experimental liver ﬁbrosis
by several days, suggesting that they may represent different
populations.
How do monocytes/macrophages promote matrix degrada-
tion? First of all, during the resolution phase, myelo-monocytic
cells serve as a source of collagen degrading enzymes, such as col-
lagenase and other matrix metalloproteinases (MMPs) [24,36,99].
Thus, increased secretion of MMP13 by hepatic macrophages is
critical for dissolution of the ﬁbrous scar in the recovering liver
[24]. In addition, macrophages are responsible for clearance of
apoptotic cells [10,58,69].
Key Points 2
Monocytes and macrophages play a dual role in the 
TGF-β1 and other cytokines and directly activate hepatic 
de novo recruitment of BM-derived monocyte/macrophage 
population or with Kupffer cells mediating alternative 
functions in response to the changing environment in the 
recovering liver
pathogenesis of liver fibrosis. They promote secretion of
myofibroblasts at the onset of liver fibrosis, but facilitate
resorbtion of fibrous scar and clearance of apoptotic cells
during resolution of liver fibrosis. Future studies must
determine if resolution of liver fibrosis is associated withFibrogenic myoﬁbroblasts
Deﬁnition of myoﬁbroblasts
Myoﬁbroblasts are characterized phenotypically by a stellate
shape and expression of stress ﬁbers, abundant pericellular
matrix and ﬁbrotic proteins (a-smooth muscle actin (a-SMA),
non-muscle myosin, ﬁbronectin, vimentin, and collagen type I)
[23]. Ultrastructurally, myoﬁbroblasts are deﬁned by prominent
rough endoplasmic reticulum (rER), a Golgi apparatus producing
collagen, peripheral myoﬁlaments, ﬁbronexus (no lamina) and
gap junctions [23]. Myoﬁbroblasts are implicated in wound heal-
ing and ﬁbroproliferative disorders [28,57]. Myoﬁbroblasts are
produced in response to ﬁbrogenic stimuli, such as TGF-b1 [65].
Classic myoﬁbroblasts differentiate from a mesenchymal lineage
and, therefore, lack expression of lymphoid markers such as CD45
or CD34. However, subsets of myoﬁbroblasts can express Thy1.1
(CD90) or CD34. It remains unclear whether expression of these
genes links (myo)ﬁbroblasts to hematopoietic stem cells, or these
antigens have a broader distribution than previously appreciated.Journal of Hepatology 201Sustained injury may trigger (trans)differentiation of myoﬁbro-
blasts from other cellular sources, including HSCs [10].
The question remains whether BM-derived cells are capable of
giving rise to the functional myoﬁbroblasts in liver ﬁbrosis. Sev-
eral BM cells have been implicated in ﬁbrogenesis, such as ﬁbro-
cytes and circulating mesenchymal cells, which could contribute
to liver ﬁbrosis.
Key Points 3
originate from different endogenous and recruited cells
The normal liver has no myofibroblasts. Liver injury may
induce the differentiation of hepatic myofibroblasts thatThe origin of ﬁbrogenic myoﬁbroblasts
Although initial reports have suggested that BM may be a source
of ﬁbrogenic myoﬁbroblasts [26,75], most recent studies have
reported that the majority of myoﬁbroblasts activated in
response to injury are from liver resident cells [37,48,49,51,81].
These ﬁndings are based on BM transplantation techniques in
mice, in which the collagen-a1(I) or collagen-a2(I) promoters
drive expression of the GFP reporter only in BM cells [37,51].
Since collagen-a1(I) or collagen-a2(I) ﬁbers are expressed in
the same cells to form a triple helix [85], these reporter genes
are expected to exhibit identical localization. Indeed, similar
results were obtained in both mice in response to two models
of liver ﬁbrosis [37,51], bile duct ligation and toxic liver injury
induced by CCl4, demonstrating that activated myoﬁbroblasts
do not originate in the BM but emerge from the liver resident
cells, e.g. HSCs and portal ﬁbroblasts. Meanwhile, a small popula-
tion of collagen type I expressing BM-derived cells, scattered in
the liver and spleen of these mice, is composed of ﬁbrocytes
[37,51]. Despite differences in experimental approaches and
duration of injury, there was no evidence that BM contributes
to replenishment of HSCs and portal ﬁbroblasts or liver stem
cells.
Fibrocytes are implicated in ﬁbrogenesis of parenchymal organs
Fibrocytes are deﬁned as spindle shaped ‘‘CD45 and collagen type
I (Col+) expressing leukocytes that mediate tissue repair and are
capable of antigen presentation to naive T cells’’ [13]. Due to their
ability to differentiate into myoﬁbroblasts, ﬁbrocytes are impli-
cated in the ﬁbrogenesis of skin, lungs, kidneys, and the liver
[1,48,87]. In addition to collagen type I, ﬁbronectin and vimentin,
ﬁbrocytes express CD45, CD34, MHCII, MHCI, CD11b, Gr-1, and
secrete growth factors (TGF-b1, MCP-1) that promote deposition
of ECM [11,70]. Upon injury or stress, ﬁbrocytes proliferate in the
BM and migrate to the injured organ [13,70]. The reported num-
ber of recruited ﬁbrocytes varies from 25% (lung ﬁbrosis) [48,88]
to 3–5% (liver ﬁbrosis, e.g. BDL and CCl4) [49] of the collagen
expressing cells, suggesting that the magnitude of ﬁbrocyte dif-
ferentiation into myoﬁbroblasts depends on the organ and the
type of injury. Fibrocytes originate from hematopoietic cells
and differentiate in the liver into typical myoﬁbroblasts [79].
Mice treated with human serum amyloid protein (hSAP) [66], a
natural inhibitor of ﬁbrocyte differentiation and maturation,
develop less ﬁbrosis in response to injury. Our data and studies2 vol. 56 j 965–972 967
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in other parenchymal organs [14,63,68] clearly demonstrate that
ﬁbrocytes play an important role in pathogenesis of many ﬁbro-
genic disorders, including lungs. Elevated levels of circulating
ﬁbrocytes in peripheral blood in patients with lung ﬁbrosis have
a poor prognostic value [62]. Moreover, hSAP has been success-
fully tested in limited clinical trials in patients with skin, kidney
and lung ﬁbrosis [14,59,63,68].
BM mesenchymal stem cells (MSCs)
MSCs are deﬁned as self-renewable, multipotent progenitor cells
with the capacity to differentiate into lineage speciﬁc cells that
form bone, cartilage, fat, tendon and muscle tissue [44,84]. Unlike
hematopoietic stem cells, MSCs are radio- and chemoresistant [9]
and do not express progenitor markers (CD45, CD34, 133 [44]) or
myelo-monocytic markers (CD11b, MHCII, and F4/80). Hepatic
myoﬁbroblasts may arise from BM-derived mesenchymal pro-
genitors [26,75]. BM-derived mesenchymal progenitors can give
rise to myoﬁbroblasts in the injured liver [6,19,55]. BM-derived
cells may populate ﬁbrotic lungs [35] and the liver [75] and con-
tribute to ﬁbrosis by differentiating into tissue myoﬁbroblasts
[40,48,75]. By subfractionating the BM stem cell compartment,
the hepatic BM-derived myoﬁbroblast-like cells were reported
to be of mesenchymal stem cell origin [44,75]. Cultured mesen-
chymal stem cells have the potential to become myoﬁbroblast-
like cells when transplanted into mouse livers [6,19].
Whether circulating mesenchymal progenitors signiﬁcantly
contribute to ECM deposition in the course of experimental liver
ﬁbrosis remains to be determined, but they most likely represent
a population, distinct from hematopoietic-derived ﬁbrocytes
[51]. Unlike hematopoietic stem cells, the deﬁnitive markers for
mesenchymal stem cells have not been identiﬁed, and ablative
radiation protocols to establish donor cell transfer have not been
standardized. Therefore, a deﬁnitive murine liver ﬁbrosis experi-
ment with documented transfer of all bone marrow constituents
expressing a myoﬁbroblast speciﬁc marker has not been
reported. Although initial enthusiasm about the BM origin of
myoﬁbroblasts declined in the recent years, further studies are
required to re-evaluate this phenomenon.
Liver ﬁbrosis precedes development of hepatocellular carci-
noma [10,38]. Recruitment of BM-derived ﬁbroblasts (including
ﬁbrocytes) has been implicated in the pathogenesis of liver can-
cer, and cancer of other organs [8]. Thus, using collagen-a1(I)-
GFP and a-smooth muscle actin (SMA)-RFP mice, BM-derived
myoﬁbroblasts were shown to contribute to neoplasia in gut
and intestine [71]. Since most liver injury models in mice develop
within a short period of time, it is possible that these experimen-
tal conditions are too short for the recruitment of BM myoﬁbro-
blasts, as seen in cancer during 8–9 months of development.
Contribution of BM cells in genetically altered mice
BM cells may have different roles in different mouse models of
genetically-induced liver injury. Since these phenomena are usu-
ally not observed in the wild type mice, contribution of BM-
derived cells to hepatic cells is discussed separately.
The classical example is FAH/ mice, in which a mutation in
fumaryl-aceto-acetate hydrolase (FAH) gene causes a metabolic
disorder equivalent to hereditary tyrosinemia type 1. Withdrawal
of the protective drug 2-(2-nitro-4-triﬂuoromethylbenzoyl)-1,3-
cyclohexanedione (NTBC) from drinking water causes extensive968 Journal of Hepatology 201apoptosis of FAH/ hepatocytes in these mice. Transplantation
of wild type BM into these mice results in rescue from fatal liver
failure by FAH-deﬁcient hepatocytes. Wild type BMmyelo-mono-
cytes cells fuse with damaged hepatocytes to give rise to colonies
of functional hepatocytes [54,98]. Moreover, infusion of myeloid
cells alone is sufﬁcient to give rise to functional hepatocytes
[3,92,101]. However, fusion of hepatocytes with macrophages
was only rarely observed in wild type mice in response to other
types of liver injury (CCl4, BDL), suggesting that hematopoietic
cells have a limited contribution to hepatocyte population under
physiological conditions or in response to injury [3,92].
Recruitment of ﬁbrocytes into the injured liver representing a
high percentage of myoﬁbroblasts has been observed in Abcb4-
deﬁcient mice (Abcb4/ mice), and has been shown to substan-
tially ameliorate development of liver ﬁbrosis [74]. However,
only a modest contribution of ﬁbrocytes to liver ﬁbrosis (3–5%
of ﬁbrogenic myoﬁbroblasts) has been observed in wild type
mice in response to CCl4 and BDL [51,79]. Although Abcb4-deﬁ-
cient mice provide a unique opportunity to study recruitment
of ﬁbrocytes in great detail, they do not reﬂect the ﬁbrocyte con-
tribution to the population of myoﬁbroblasts in hepatotoxic or
cholestatic injury.Resolution of liver ﬁbrosis
Disappearance of myoﬁbroblasts
Reversal of ﬁbrosis is associated with increased collagenase
activity, activation of macrophages/Kupffer cells that secrete
matrix metalloproteinases, e.g. MMP-13, and matrix degradation
[24,95]. Senescence and apoptosis of activated HSCs play a signif-
icant role in resolution of liver ﬁbrosis by eliminating the cell
type responsible for producing the ﬁbrotic scar [41,53]. Several
mechanisms are implicated in the apoptosis of activated HSC:
(1) activation of death receptor-mediated pathways (Fas or
TNFR-1 receptors) and caspases 8 and 3; (2) upregulation of
pro-apoptotic proteins (e.g., p53, Bax, caspase 9); and (3)
decrease of pro-survival genes (e.g., Bcl-2) [50]. A population of
liver-associated natural killer (NK) cells and NKT cells mediate
apoptosis of activated HSCs [72]. Kupffer cells and BM macro-
phages actively participate in clearance of apoptotic cells and
degradation of extracellular matrix proteins.
Studies in culture suggest that aHSCs, at least in part, can
revert to a quiescent phenotype. Therefore, the disappearance
of activated a-SMA+ Col+ HSCs in the course of ﬁbrosis reversal
may indicate that activated HSCs return to their quiescent state,
which is associated with expression of lipogenic genes (Adfp,
Adipor1, CREBP, PPAR-c) [83] and storage of vitamin A in lipid
droplets. Depletion of peroxisome proliferator-activated receptor
gamma (PPAR-c) constitutes a key molecular event for HSC acti-
vation, and ectopic over-expression of this nuclear receptor
results in the phenotypic reversal of activated HSC to quiescent
cells in culture [83]. The treatment of activated HSCs with an adi-
pocyte differentiation cocktail, over-expression of SREBP-1c, or
culturing on basement membrane-like ECM [29,100] result in
up-regulation of adipogenic transcription factors and cause mor-
phologic and biochemical reversal of activated HSCs to quiescent
cells [93,94]. Although these results suggest that activated HSCs
can revert to a quiescent state, these ﬁndings have only been












Fig. 2. Potential roles of BM-derived progenitor populations in liver injury.
BM is the source of hematopoietic and mesenchymal stem cells, which may
participate in the response to liver injury.
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Therapy
Many studies have demonstrated that transplantation of bone
marrow cells reduces experimental liver ﬁbrosis ([76,90] and
others). The mechanism is not trans-differentiation of bone mar-
row cells into hepatocytes. More likely, hematological stem cells
may contribute to the reversal of liver ﬁbrosis via macrophages
that produce collagenases [91] and phagocytose dead parenchy-
mal cells [69]. More unexpectedly, mesenchymal stem cells, even
though they have the potential to become myoﬁbroblasts, also
have functions that may contribute to the reversal of ﬁbrosis. Cul-
tured mesenchymal stem cells secrete agonists that inhibit hepa-
tocyte apoptosis, induce hepatocyte proliferation, and increase
hepatocyte speciﬁc gene expression [96]. Also, mesenchymal
stem cells may be induced in culture to become endothelial pro-
genitor cells (EPCs). Transplantation of EPCs reverses hepatic
ﬁbrosis and improves survival in CCl4-induced cirrhosis in rats
[64].
BM cells for anti-ﬁbrotic therapy
The improvement of liver function following transplantation of
hematopoietic progenitors in mice and rats with injured livers
provided the basis for clinical trials [25]. Clinical studies with
adoptive transfer of autologous CD133+ BM cells in patients have
been reported to stimulate liver regeneration [4]. Similar to that,
autologous infusion of CD34+ blood cells, or even monocytes,
improved biochemical parameters and stimulated liver regenera-
tion [33]. Within the limits of these small, uncontrolled clinical
trials, evidence is starting to accumulate that transplantation of
hematopoietic progenitors may be beneﬁcial in patients. How-
ever, the mechanism of their action remains to be deﬁned. Such
improvement may result from release of cytokines and growth
factors by transplanted hematopoietic cells, or occur due to infu-
sion of scar-resorbing monocytes. In concordance with these
observations, treatment with granulocyte-colony stimulating fac-
tor (G-CSF) was used to mobilize the BM cells and demonstrated
a positive histological effect in patients with alcoholic steatohep-
atitis [30].
Mesenchymal stem cells serve as another potential target for
the liver stem cell therapy. In addition, mesenchymal cells are
readily available (for example, from fat tissue) and relatively easy
to expand in vitro. A recent study investigated the ability of puri-
ﬁed hematopoietic stem cells (HSCs), mesenchymal stem cells
(MSCs), and mononuclear cells to engraft and contribute to liver
regeneration in response to injury in mice [15]. However, only a
low level of engraftment with the MSCs and reconstitution of the
liver mass has been reported [7].
In concordance with this notion, injection of MSC-derived
conditioning media into a liver-assist device decreased hepato-
cyte apoptosis and increased their proliferation [96,103]. How-
ever, recent studies have raised a safety question on MSCs
transplantation, demonstrating that MSCs can give rise to myoﬁ-
broblasts in mice in response to liver injury. For example, BM-
derived MSCs contributed to the development of liver ﬁbrosis
in chimeric mice that received bone marrow transplantation with
an enriched BMmesenchymal fraction, and subjected to the CCl4-
liver injury [75]. Taken together, both hematopoietic and mesen-
chymal stem cells demonstrate a limited, if any, contribution to
hepatocyte replenishment, but may stimulate liver function by
providing soluble growth factors or cytokines [3,49,92].Journal of Hepatology 201A few clinical trials have been performed in patients with end-
stage liver disease caused by hepatitis B, hepatitis C, alcoholic
liver disease, and cryptogenic ﬁbrosis. These patients were trans-
planted with autologous MSCs harvested from the iliac crest. The
tested parameters (albumin, creatinine) demonstrated a modest
but signiﬁcant improvement without severe adverse effects, sug-
gesting that MSCs might be useful for the treatment of end-stage
liver disease with satisfactory tolerability [47].Conclusions
The literature provides evidence that bone marrow cells might
contribute to increase or to inhibit experimental liver ﬁbrosis
(Fig. 2). Although there is clearly a need for additional, better
deﬁned studies, some conclusions can be made from our current
information. Hematological stem cells are the source of mono-
cytes, Kupffer cells and recruited macrophage. Overall, these cells
contribute to the initial inﬂammation in the injured liver that
progresses to liver ﬁbrosis. However, recruited macrophages
may also secrete agonists such as IL-10 that inhibit stellate cell
activation as well as collagenases that cause regression of ﬁbro-
sis. Hematological stem cells are also the source of ﬁbrocytes,
which are recruited to the injured liver and function in the innate
immune response as well as differentiate into myoﬁbroblasts.
Mesenchymal stem cells have the capacity to become myoﬁbro-
blasts, but studies to follow their cell fate in vivo are limited by
the lack of speciﬁc markers.2 vol. 56 j 965–972 969
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Most, but not all, studies using BM transplantation have dem-
onstrated a beneﬁcial effect on experimental liver ﬁbrosis. The
mechanism for this beneﬁt is unclear, and in particular BM-
derived cells do not constitute a signiﬁcant source of hepatocytes
in the injured liver. However, both mesenchymal stem cells and
hematopoietic stem cells are reported to contribute to the regres-
sion of liver ﬁbrosis. On the basis of these studies, small, mostly
uncontrolled clinical studies have treated cirrhotic patients with
autologous transplantation of BM derived cells. Although these
studies have established the feasibility of this approach, the
mechanism and long term beneﬁt of transplantation of BM-
derived cells in cirrhosis is unknown.Conﬂict of interest
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